Long-term efficacy of radical treatment of patients with clear cell sarcoma
European Journal of Surgical Oncology · 2026
DOI: 10.1016/j.ejso.2026.111485 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von Anna M Czarnecka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Ou…. Hauptthemen laut MEDLINE: Sarcoma, Clear Cell. Die Arbeit nennt 62 Literaturangaben. Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
BACKGROUND: Clear cell sarcoma (CCS) is a rare subtype of soft tissue sarcoma (STS). The objective of this analysis was to evaluate the effectiveness of multidisciplinary treatment of CCS and to identify potential factors that influence the outcome. METHODS: A retrospective analysis of curative-intent treatment of CCS patients between 1998 and 2024 in the sarcoma reference centre. RESULTS: The median Relapse-free Survival (RFS) and Overall Survival (OS) times were 33.1 (95% CI: 11.1-Not Reached, NR) and 55.5 (95% CI: 37.4-NR) months, respectively. One year after the surgery, the RFS was 63.5% (95% CI: 49.5-81.5), and at three and five years it was 41.8% (95% CI: 28-62.4) and 38.3% (95% CI: 24.8-59.2), respectively. Three years after the surgery 64.7% (95% CI: 50.3-83.2) of patients were alive, and at five years - 49.3% (95% CI: 34.1-71.2). Among 19 patients referred for sentinel lymph node biopsy (SLNB), it was positive in 8 (42.1%) patients, at the same time lymph node dissection (LND) was performed in 4 patients. Excluding patients undergoing electrochemotherapy and wide excision of scar, the R0 resection margins were achieved in 14 (48.3%) patients. Those patients had superior RFS compared to patients with R1/2 resection margins: 83 (95% CI: 14.8-NR) months and 11.1 (95% CI: 5.9-NR) months, respectively (p = 0.0095). We observed a similar trend for OS, where patients with R0 margins had NR (95% CI: 30-NR) compared to 37.4 (95% CI: 10.6-NR) in the case of R1/2 margins, p = 0.051. CONCLUSIONS: Consequently, SLNB and LND procedures should be offered more often to patients with this diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Outpatient Chemotherapy, Maria Sklodowska-Curie National Research Instit…
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Medical Faculty, Medical University of Warsaw, Warsaw, Poland; Doctoral School of Mole…
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Computational Oncology, Maria Sklodowska-Curie National Research Institu…
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of On…
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Czarnecka, A. M., Błoński, P., Chmiel, P., Zdzienicki, M., Szumera-Ciećkiewicz, A., Pieńkowski, A., Teterycz, P., Spałek, M. J., Świtaj, T., Falkowski, S., Wągrodzki, M., & Rutkowski, P. (2026). Long-term efficacy of radical treatment of patients with clear cell sarcoma. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2026.111485
Vancouver
Czarnecka AM, Błoński P, Chmiel P, Zdzienicki M, Szumera-Ciećkiewicz A, Pieńkowski A, et al. Long-term efficacy of radical treatment of patients with clear cell sarcoma. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2026.111485
BibTeX
@article{Czarnecka2026,
author = {Czarnecka, Anna M and Błoński, Piotr and Chmiel, Paulina and Zdzienicki, Marcin and Szumera-Ciećkiewicz, Anna and Pieńkowski, Andrzej and Teterycz, Paweł and Spałek, Mateusz Jacek and Świtaj, Tomasz and Falkowski, Sławomir and Wągrodzki, Michał and Rutkowski, Piotr},
title = {Long-term efficacy of radical treatment of patients with clear cell sarcoma},
journal = {European Journal of Surgical Oncology},
year = {2026},
doi = {10.1016/j.ejso.2026.111485}
}
EUVIMED